{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:07:22Z","timestamp":1772827642480,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.yexmp.2024.104916","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T10:28:25Z","timestamp":1719916105000},"page":"104916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds"],"prefix":"10.1016","volume":"138","author":[{"given":"Sarah J.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Hollis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Simon","family":"Herrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon P.","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yexmp.2024.104916_bb0005","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41594-020-0380-1","article-title":"FANCD2-FANCI is a clamp stabilized on DNA by monoubiquitination of FANCD2 during DNA repair","volume":"27","author":"Alcon","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104916_bb0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"7353","key":"10.1016\/j.yexmp.2024.104916_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.yexmp.2024.104916_bb0020","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1158\/0008-5472.CAN-11-3911","article-title":"The changing view of high-grade serous ovarian Cancer","volume":"72","author":"Berns","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2024.104916_bb0025","first-page":"6","article-title":"FANCD2 functions as a critical factor downstream of MiTF to maintain the proliferation and survival of melanoma cells","author":"Bourseguin","year":"2016","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.yexmp.2024.104916_bb0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.yexmp.2024.104916_bb0035","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1093\/nar\/gkw036","article-title":"Delta Np63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma","volume":"44","author":"Bretz","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.yexmp.2024.104916_bb0040","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13402-016-0291-7","article-title":"The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells","volume":"39","author":"Chen","year":"2016","journal-title":"Cell. Oncol."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104916_bb0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"issue":"35","key":"10.1016\/j.yexmp.2024.104916_bb0050","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1038\/onc.2010.245","article-title":"Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma","volume":"29","author":"Cooke","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.yexmp.2024.104916_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104916_bb0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3816\/CLC.2005.n.005","article-title":"FANCD2 expression in advanced non\u2013small-cell Lung Cancer and response to platinum-based chemotherapy","volume":"6","author":"Ferrer","year":"2005","journal-title":"Clin. Lung Cancer"},{"issue":"37","key":"10.1016\/j.yexmp.2024.104916_bb0065","doi-asserted-by":"crossref","first-page":"24707","DOI":"10.18632\/oncotarget.25185","article-title":"Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts","volume":"9","author":"Guffanti","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.yexmp.2024.104916_bb0070","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/leu.2013.93","article-title":"mTOR regulates DNA damage response through NF-kappa B-mediated FANCD2 pathway in hematopoietic cells","volume":"27","author":"Guo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.yexmp.2024.104916_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216057","article-title":"Molecular characteristics and clinical behaviour of epithelial ovarian cancers","volume":"555","author":"Hollis","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexmp.2024.104916_bb0080","first-page":"10","article-title":"Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer","author":"Hollis","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"16","key":"10.1016\/j.yexmp.2024.104916_bb0085","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1158\/1078-0432.CCR-22-0368","article-title":"Multiomic characterization of high-grade serous ovarian carcinoma enables high-resolution patient stratification","volume":"28","author":"Hollis","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.yexmp.2024.104916_bb0090","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1101\/gad.1103403","article-title":"Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice","volume":"17","author":"Houghtaling","year":"2003","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.yexmp.2024.104916_bb0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/path.1450","article-title":"FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anaemia","volume":"201","author":"H\u00f6zel","year":"2003","journal-title":"J. Pathol."},{"issue":"8","key":"10.1016\/j.yexmp.2024.104916_bb0100","doi-asserted-by":"crossref","first-page":"775","DOI":"10.18632\/oncotarget.27437","article-title":"Subcellular localization of FANCD2 is associated with survival in ovarian carcinoma","volume":"11","author":"Joshi","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.yexmp.2024.104916_bb0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2009.11.009","article-title":"Fanconi Anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments","volume":"292","author":"Kachnic","year":"2010","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104916_bb0110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/517616","article-title":"Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype","volume":"80","author":"Kalb","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.yexmp.2024.104916_bb0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/ncomms4156","article-title":"Integrated analysis of germline and somatic variants in ovarian cancer","volume":"5","author":"Kanchi","year":"2014","journal-title":"Nat. Commun."},{"issue":"5960","key":"10.1016\/j.yexmp.2024.104916_bb0120","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1126\/science.1182372","article-title":"The Fanconi Anemia pathway promotes replication-dependent DNA Interstrand cross-link repair","volume":"326","author":"Knipscheer","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.yexmp.2024.104916_bb0125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/annonc\/mdr063","article-title":"Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179)","volume":"23","author":"Kollmannsberger","year":"2012","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.yexmp.2024.104916_bb0130","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.21873\/anticanres.11420","article-title":"Clinical significance of FANCD2 gene expression and its association with tumor progression in hepatocellular carcinoma","volume":"37","author":"Komatsu","year":"2017","journal-title":"Anticancer Res."},{"issue":"59","key":"10.1016\/j.yexmp.2024.104916_bb0135","article-title":"Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer","volume":"1","author":"Konstantinopoulos","year":"2009","journal-title":"BMC Med. Genet."},{"issue":"12","key":"10.1016\/j.yexmp.2024.104916_bb0140","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1038\/bjc.2014.258","article-title":"Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer","volume":"110","author":"Koussounadis","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"21","key":"10.1016\/j.yexmp.2024.104916_bb0145","first-page":"6166","article-title":"Characterization and properties of 9 human ovarian adenocarcinoma cell lines","volume":"48","author":"Langdon","year":"1988","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.yexmp.2024.104916_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092545","article-title":"FANCD2 confers a malignant phenotype in esophageal squamous cell carcinoma by regulating cell cycle progression","volume":"12","author":"Lei","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.yexmp.2024.104916_bb0155","article-title":"FANCD2 inhibits ferroptosis by regulating the JAK2\/STAT3 pathway in osteosarcoma","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.yexmp.2024.104916_bb0160","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00404-014-3377-3","article-title":"PI3K\/AKT\/mTOR signaling pathway as a therapeutic target for ovarian cancer","volume":"290","author":"Li","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"issue":"7","key":"10.1016\/j.yexmp.2024.104916_bb0165","first-page":"12","article-title":"Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers","volume":"107","author":"Liu","year":"2015","journal-title":"Jnci-J. National Cancer Instit."},{"issue":"16","key":"10.1016\/j.yexmp.2024.104916_bb0170","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00018-016-2218-x","article-title":"Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway","volume":"73","author":"Lopez-Martinez","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"15","key":"10.1016\/j.yexmp.2024.104916_bb0175","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1158\/0008-5472.CAN-04-2684","article-title":"Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer","volume":"65","author":"Macleod","year":"2005","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.yexmp.2024.104916_bb0180","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.molcel.2005.08.018","article-title":"A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair","volume":"19","author":"Matsushita","year":"2005","journal-title":"Mol. Cell"},{"key":"10.1016\/j.yexmp.2024.104916_bb0185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ebiom.2019.10.062","article-title":"Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin","volume":"50","author":"Metselaar","year":"2019","journal-title":"Ebiomedicine"},{"issue":"6","key":"10.1016\/j.yexmp.2024.104916_bb0190","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/15384047.2019.1579955","article-title":"Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas","volume":"20","author":"Moes-Sosnowska","year":"2019","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104916_bb0195","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/path.3980","article-title":"The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer","volume":"226","author":"Ng","year":"2012","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.yexmp.2024.104916_bb0200","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1245\/s10434-010-1002-7","article-title":"FANCD2 mRNA overexpression is a Bona fide Indicator of lymph node metastasis in human colorectal Cancer","volume":"17","author":"Ozawa","year":"2010","journal-title":"Ann. Surg. Oncol."},{"issue":"18","key":"10.1016\/j.yexmp.2024.104916_bb0205","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1158\/0008-5472.CAN-06-0222","article-title":"Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer","volume":"66","author":"Pejovic","year":"2006","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104916_bb0210","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/0008-5472.CAN-07-2418","article-title":"Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer","volume":"68","author":"Potapova","year":"2008","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.yexmp.2024.104916_bb0215","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"issue":"8","key":"10.1016\/j.yexmp.2024.104916_bb0220","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1158\/1078-0432.CCR-15-2209","article-title":"Defects in the Fanconi Anemia pathway in head and neck Cancer cells stimulate tumor cell invasion through DNA-PK and Rac1 signaling","volume":"22","author":"Romick-Rosendale","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.yexmp.2024.104916_bb0225","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2353\/ajpath.2010.090779","article-title":"Significance of the Fanconi Anemia FANCD2 protein in sporadic and metastatic human breast cancer","volume":"176","author":"Rudland","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"16","key":"10.1016\/j.yexmp.2024.104916_bb0230","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","article-title":"Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma","volume":"69","author":"Sakai","year":"2009","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.yexmp.2024.104916_bb0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1371\/journal.pmed.1001789","article-title":"Spatial and temporal heterogeneity in high-grade serous ovarian Cancer: a phylogenetic analysis","volume":"12","author":"Schwarz","year":"2015","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.yexmp.2024.104916_bb0240","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1158\/0008-5472.CAN-12-4282","article-title":"Regulation of FANCD2 by the mTOR pathway contributes to the resistance of Cancer cells to DNA double-Strand breaks","volume":"73","author":"Shen","year":"2013","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.yexmp.2024.104916_bb0245","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res."},{"issue":"34","key":"10.1016\/j.yexmp.2024.104916_bb0250","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian Cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian Cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104916_bb0255","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nm852","article-title":"Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors","volume":"9","author":"Taniguchi","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.yexmp.2024.104916_bb0260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.37349\/etat.2020.00003","article-title":"Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer","volume":"1","author":"Taylor","year":"2020","journal-title":"Explorat. Target. Antitumor Therap."},{"key":"10.1016\/j.yexmp.2024.104916_bb0265","article-title":"Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context","volume":"56","author":"Timpson","year":"2011","journal-title":"Jove-J. Visualiz. Experiment."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104916_bb0270","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian Cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"Ca-a Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104916_bb0275","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-007-9534-7","article-title":"Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer","volume":"107","author":"van der Groep","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.yexmp.2024.104916_bb0280","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2021.07.008","article-title":"The effectiveness of monotherapy with PI3K\/AKT\/mTOR pathway inhibitors in ovarian cancer: a meta-analysis","volume":"163","author":"van der Ploeg","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.yexmp.2024.104916_bb0285","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/cas.12679","article-title":"Celastrol induces proteasomal degradation of FANCD2 to sensitize lung cancer cells to DNA crosslinking agents","volume":"106","author":"Wang","year":"2015","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104916_bb0290","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s13402-020-00514-8","article-title":"The PI3K\/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis","volume":"43","author":"Xiao","year":"2020","journal-title":"Cell. Oncol."},{"issue":"28","key":"10.1016\/j.yexmp.2024.104916_bb0295","doi-asserted-by":"crossref","first-page":"26457","DOI":"10.18632\/oncotarget.4762","article-title":"MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR\/P70S6K1","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.yexmp.2024.104916_bb0300","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/bjc.2016.103","article-title":"Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response","volume":"114","author":"Zakaria","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.yexmp.2024.104916_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113388","article-title":"FANCD2 promotes the malignant behavior of endometrial cancer cells and its prognostic value","volume":"421","author":"Zheng","year":"2022","journal-title":"Exp. Cell Res."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480024000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480024000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T05:38:53Z","timestamp":1728279533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480024000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":61,"alternative-id":["S0014480024000352"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2024.104916","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FANCD2 expression affects platinum response and further characteristics of high grade serous ovarian cancer in cells with different genetic backgrounds","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2024.104916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104916"}}